Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

Seeking a faster, sharper ComCom
Economy

Seeking a faster, sharper ComCom

A ‘gold standard’ approach and siloed structure slow the ComCom down.

NZ dollar on watch ahead of 3Q GDP, Fed signals
Markets

NZ dollar on watch ahead of 3Q GDP, Fed signals

Economists expect NZ GDP to shrink 0.3% in the June quarter after March growth.

Craigs beefs up in Hawkes Bay, eyes further expansion
Finance

Craigs beefs up in Hawkes Bay, eyes further expansion

Craigs looks to further expansion as it confirms the Somerset Smith Partners deal.

NZ sharemarket drifts flat as Fed decision looms
Markets Market Close

NZ sharemarket drifts flat as Fed decision looms

The S&P/NZX 50 Index closed down 0.05% or 6.5 points.

Tom Raynel 17 Sep 2025